{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:33:29Z","timestamp":1788287609313,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"am","delay-in-days":265,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI150300-01S1"],"award-info":[{"award-number":["R01AI150300-01S1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32HD075735"],"award-info":[{"award-number":["T32HD075735"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coi.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T18:17:37Z","timestamp":1624472257000},"page":"196-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Down syndrome and type I interferon: not so simple"],"prefix":"10.1016","volume":"72","author":[{"given":"Louise","family":"Malle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2021.06.006_bib0005","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/bdr2.1589","article-title":"National population-based estimates for major birth defects, 2010\u20132014","volume":"111","author":"Mai","year":"2019","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.coi.2021.06.006_sbref0010","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMra1706537","article-title":"Down syndrome","volume":"382","author":"Bull","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2021.06.006_sbref0015","first-page":"1","article-title":"Down syndrome","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coi.2021.06.006_bib0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/gim.2016.127","article-title":"Estimation of the number of people with Down syndrome in the United States","volume":"19","author":"De Graaf","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0025","series-title":"Dermatological Manifestations of Down\u2019s Syndrome","author":"Madan","year":"2006"},{"key":"10.1016\/j.coi.2021.06.006_bib0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/INF.0000000000002666","article-title":"Respiratory syncytial virus-related death in children with Down syndrome: the RSV GOLD study","volume":"39","author":"L\u00f6wensteyn","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coi.2021.06.006_bib0035","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1608.091931","article-title":"Pandemic (H1N1) 2009 virus and Down syndrome patients","volume":"16","author":"P\u00e9rez-Padilla","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coi.2021.06.006_bib0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.7326\/M20-4986","article-title":"COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults","volume":"174","author":"Clift","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0045","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.07.020413","article-title":"The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: a systematic review and meta-analysis","volume":"7","author":"Chan","year":"2017","journal-title":"J Glob Health"},{"key":"10.1016\/j.coi.2021.06.006_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2249.2011.04335.x","article-title":"Infections and immunodeficiency in Down syndrome","volume":"164","author":"Ram","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0055","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41436-020-01004-w","article-title":"Individuals with Down syndrome hospitalized with COVID-19 have more severe disease","volume":"23","author":"Malle","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3389\/fimmu.2020.00840","article-title":"Immune defect in adults with Down syndrome: insights into a complex issue","volume":"11","author":"Dieudonn\u00e9","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.06.006_sbref0065","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10875-020-00805-7","article-title":"Inborn errors of adaptive immunity in Down syndrome","volume":"40","author":"Verstegen","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0070","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling","volume":"292","author":"Schreiber","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2021.06.006_bib0075","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.4049\/jimmunol.1800764","article-title":"The goldilocks zone of type I IFNs: lessons from human genetics","volume":"201","author":"Taft","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0080","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1126\/science.186.4158.61","article-title":"Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state","volume":"186","author":"Tan","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.06.006_sbref0090","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014723118","article-title":"Consequences of aneuploidy in human fibroblasts with trisomy 21","volume":"118","author":"Hwang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.06.006_bib0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2021.06.006_bib0100","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1128\/MCB.01808-08","article-title":"Receptor density is key to the alpha2\/beta interferon differential activities","volume":"29","author":"Moraga","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coi.2021.06.006_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12273-8","article-title":"Single cell transcriptome in aneuploidies reveals mechanisms of gene dosage imbalance","volume":"10","author":"Stamoulis","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.06.006_bib0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.2429366","article-title":"An early event in the interferon-induced transmembrane signaling process","volume":"234","author":"Yap","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.06.006_bib0115","doi-asserted-by":"crossref","first-page":"e16220","DOI":"10.7554\/eLife.16220","article-title":"Trisomy 21 consistently activates the interferon response","volume":"5","author":"Sullivan","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.coi.2021.06.006_bib0120","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","article-title":"Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome","volume":"29","author":"Waugh","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2021.06.006_sbref0125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","article-title":"Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome","volume":"40","author":"Kong","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194581","article-title":"Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21","volume":"13","author":"Gonzales","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2021.06.006_bib0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors\u2014distribution and regulation","volume":"90","author":"Weerd","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.coi.2021.06.006_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13476","article-title":"Spatiotemporal control of interferon-induced JAK\/STAT signalling and gene transcription by the retromer complex","volume":"7","author":"Chmiest","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.06.006_bib0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ana.25752","article-title":"Dysregulation of the retromer complex system in Down syndrome","volume":"88","author":"Curtis","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2021.06.006_bib0150","first-page":"ana.26042","article-title":"Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer disease pathology","author":"Filippone","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coi.2021.06.006_sbref0155","doi-asserted-by":"crossref","first-page":"24231","DOI":"10.1073\/pnas.1908129116","article-title":"Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity","volume":"116","author":"Araya","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.06.006_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12739-9","article-title":"Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors","volume":"10","author":"Powers","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.06.006_bib0165","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39629","article-title":"Association of increased Treg cell levels with elevated indoleamine 2,3-dioxygenase activity and an imbalanced kynurenine pathway in interferon-positive primary Sj\u00f6gren\u2019s syndrome","volume":"68","author":"Maria","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2021.06.006_bib0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00702-011-0681-y","article-title":"The kynurenine system and immunoregulation","volume":"119","author":"M\u00e1ndi","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/j.coi.2021.06.006_bib0175","series-title":"Article JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome","author":"Tuttle","year":"2020"},{"key":"10.1016\/j.coi.2021.06.006_bib0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrg.2016.154","article-title":"Down syndrome and the complexity of genome dosage imbalance","volume":"18","author":"Antonarakis","year":"2017","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coi.2021.06.006_bib0185","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.1224026","article-title":"Mycobacterial disease and impaired IFN-\u03b3 immunity in humans with inherited ISG15 deficiency","volume":"337","author":"Bogunovic","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.06.006_bib0190","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.20151529","article-title":"Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome","volume":"213","author":"Meuwissen","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0195","doi-asserted-by":"crossref","first-page":"17510","DOI":"10.1073\/pnas.1921324117","article-title":"Type I IFN is siloed in endosomes","volume":"117","author":"Altman","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.06.006_bib0200","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-8-354","article-title":"Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells","volume":"8","author":"Su","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.coi.2021.06.006_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046082","article-title":"MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1","volume":"7","author":"Yao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2021.06.006_bib0210","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fphys.2018.00686","article-title":"MiRNA-155 regulates the Th17\/Treg ratio by targeting SOCS1 in severe acute pancreatitis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.coi.2021.06.006_bib0215","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10571-017-0514-0","article-title":"Chromosome 21-encoded microRNAs (mRNAs):impact on Down\u2019s syndrome and trisomy-21 linked disease","volume":"38","author":"Alexandrov","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.coi.2021.06.006_bib0220","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2018.02683","article-title":"Dysregulated miR-155 and miR-125b are related to impaired B-cell responses in Down syndrome","volume":"9","author":"Farroni","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0225","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/pbc.24246","article-title":"Increased circulating apoptotic lymphocytes in children with Down syndrome","volume":"59","author":"Gemen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.coi.2021.06.006_bib0230","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<406::AID-AJMG4>3.0.CO;2-4","article-title":"Presenility of granulocytes in Down syndrome individuals","volume":"84","author":"Yasui","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.coi.2021.06.006_bib0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The type I interferonopathies","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coi.2021.06.006_bib0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1749-6632.1982.tb26852.x","article-title":"Basal Ganglia Calcification (BGC) in Down\u2019s Syndrome (DS)\u2014another manifestation of premature aging","volume":"396","author":"Wisniewski","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2021.06.006_bib0245","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00342687","article-title":"A morphometric CT study of Down\u2019s syndrome showing small posterior fossa and calcification of basal ganglia","volume":"26","author":"Ieshima","year":"1984","journal-title":"Neuroradiology"},{"key":"10.1016\/j.coi.2021.06.006_bib0250","series-title":"Basal Ganglia Calcification in Down\u2019s Syndrome","author":"Takashima","year":"1985"},{"key":"10.1016\/j.coi.2021.06.006_bib0255","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243180","article-title":"Intracranial calcification and seizures in Down syndrome","volume":"14","author":"Panda","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.coi.2021.06.006_bib0260","first-page":"54","article-title":"Observations on an ethnic classification of idiots","volume":"33","author":"Down","year":"1866","journal-title":"Ment Retard"},{"key":"10.1016\/j.coi.2021.06.006_bib0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1469-8749.1991.tb05108.x","article-title":"Seizures in children with Down syndrome: etiology, characteristics and outcome","volume":"33","author":"Stafstrom","year":"1991","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.coi.2021.06.006_bib0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12969-016-0094-4","article-title":"Type I interferonopathies in pediatric rheumatology","volume":"14","author":"Volpi","year":"2016","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.coi.2021.06.006_bib0275","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/pde.14326","article-title":"Hidradenitis suppurativa and Down syndrome: a systematic review and meta-analysis","volume":"37","author":"Lam","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.coi.2021.06.006_bib0280","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2020.00475","article-title":"Designation of autoinflammatory skin manifestations with specific genetic backgrounds","volume":"11","author":"Kanazawa","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0285","unstructured":"Overview of Cutaneous Lupus Erythematosus - UpToDate. Available: https:\/\/www-uptodate-com.eresources.mssm.edu\/contents\/overview-of-cutaneous-lupus-erythematosus?search=sle&topicRef=4668&source=see_link. [Accessed: 01 April 2021]."},{"key":"10.1016\/j.coi.2021.06.006_sbref0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","article-title":"CASE REPORT Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata","volume":"5","author":"Rachubinski","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2021.06.006_bib0295","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab203","article-title":"JAK inhibition for treatment of psoriatic arthritis in Down syndrome","author":"Pham","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coi.2021.06.006_bib0300","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.coi.2021.06.006_bib0305","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11496","article-title":"ISG15 deficiency and increased viral resistance in humans but not mice","volume":"7","author":"Speer","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2021.06.006_bib0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2021.06.006_bib0315","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2021.06.006_bib0320","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Auto-antibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.06.006_bib0325","doi-asserted-by":"crossref","first-page":"84489","DOI":"10.18632\/oncotarget.21060","article-title":"Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coi.2021.06.006_bib0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13858-3","article-title":"Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation","volume":"7","author":"Sullivan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2021.06.006_bib0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/039463200501800117","article-title":"Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer\u2019s type","volume":"18","author":"Licastro","year":"2005","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.coi.2021.06.006_bib0340","doi-asserted-by":"crossref","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0345","first-page":"25","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations key points","volume":"21","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.06.006_bib0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2021.06.006_bib0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1749-6632.1980.tb20602.x","article-title":"Interferon\u2010induced disease in mice and rats","volume":"350","author":"Gresser","year":"1980","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2021.06.006_bib0360","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0006-8993(99)01328-1","article-title":"Structural and functional neuropathology in transgenic mice with CNS expression of IFN-\u03b1","volume":"835","author":"Campbell","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.coi.2021.06.006_sbref0365","doi-asserted-by":"crossref","DOI":"10.1172\/JCI134529","article-title":"TLR3 controls constitutive IFN-\u03b2 antiviral immunity in human fibroblasts and cortical neurons","volume":"131","author":"Gao","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2021.06.006_bib0370","series-title":"Partial IFN-a \/b and IFN-g Receptor Knockout Trisomy 16 Mouse Fetuses Show Improved Growth and Cultured Neuron Viability","author":"Maroun","year":"2000"},{"key":"10.1016\/j.coi.2021.06.006_bib0375","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/tera.1420510509","article-title":"Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype","volume":"51","author":"Maroun","year":"1995","journal-title":"Teratology"},{"key":"10.1016\/j.coi.2021.06.006_bib0380","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.immuni.2018.07.017","article-title":"Interferons and proinflammatory cytokines in pregnancy and fetal development","volume":"49","author":"Yockey","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2021.06.006_sbref0385","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1126\/science.aaw7733","article-title":"IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise","volume":"365","author":"Buchrieser","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.coi.2021.06.006_bib0390","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/pd.1443","article-title":"Maternal age-specific fetal loss rates in Down syndrome pregnancies","volume":"26","author":"Savva","year":"2006","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.coi.2021.06.006_bib0395","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.placenta.2019.10.002","article-title":"Placental development and function in trisomy 21 and mouse models of Down syndrome: clues for studying mechanisms underlying atypical development","volume":"89","author":"Adams","year":"2020","journal-title":"Placenta"},{"issue":"Suppl. 1","key":"10.1016\/j.coi.2021.06.006_bib0400","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.coi.2021.06.006_bib0405","unstructured":"Tofacitinib for Immune Skin Conditions in Down Syndrome - Full Text View - ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04246372. [Accessed: 17 May 2021]."}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791521000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791521000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:49:13Z","timestamp":1760604553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791521000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":81,"alternative-id":["S0952791521000765"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2021.06.006","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Down syndrome and type I interferon: not so simple","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}